Vaxcyte (PCVX) Total Non-Current Liabilities (2019 - 2025)

Vaxcyte (PCVX) has 7 years of Total Non-Current Liabilities data on file, last reported at $317.1 million in Q4 2025.

• On a quarterly basis, Total Non-Current Liabilities rose 54.39% year-over-year to $317.1 million in Q4 2025; TTM through Dec 2025 was $317.1 million, a 54.39% increase from a year earlier, with the FY2025 full-year figure at $317.1 million, up 54.39% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $317.1 million, up from $205.4 million in the prior quarter.
• Over the last five years, Total Non-Current Liabilities for PCVX reached as high as $317.1 million in Q4 2025 and fell as low as $40.2 million in Q4 2021.
• Historically, Total Non-Current Liabilities has averaged $92.4 million across 5 years, with a median of $54.0 million in 2021.
• Across the five-year window, Total Non-Current Liabilities slipped 22.11% in 2022 and soared 218.61% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $40.2 million in 2021, then soared by 30.66% to $52.6 million in 2022, then surged by 218.61% to $167.4 million in 2023, then climbed by 22.66% to $205.4 million in 2024, then surged by 54.39% to $317.1 million in 2025.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $317.1 million in Q4 2025, $205.4 million in Q4 2024, and $167.4 million in Q4 2023.